Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683691 · ClinicalTrials.gov registry record · NA
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
A NA study of Prostate Cancer, sponsored by Francis Medical.
- Active
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT05683691: Active NA study of Prostate Cancer, sponsored by Francis Medical.
NCT05683691 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Francis Medical. The registered enrollment target is 400 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05683691, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Francis Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Primary Outcome
Freedom from systemic disease AND systemic therapy AND salvage therapy AND GGG≥2.
Conditions Studied
Interventions
- DEVICE Vanquish System
Study Locations (20)
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic- Rochester - Rochester
- Minnesota Urology - Woodbury
New York
- NYU Langone Health - New York
- Northwell Health- Lenox Hill Hospital - New York
- University of Rochester - Rochester
California
- Memorial Care - Laguna Hills
- University of Southern California - Los Angeles
Maryland
- Chesapeake Urology - Baltimore
- Johns Hopkins - Baltimore
Michigan
- Corewell Health / William Beaumont University Hospital - Royal Oak
- Michigan Institute of Urology - Troy
Arizona
- Mayo Clinic- Phoenix - Phoenix
Florida
- Kasraeian Urology - Jacksonville
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2029-04 |
| Phase | NA |
What the registry record for NCT05683691 still lists
NCT05683691 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Vanquish System is the first listed.
NCT05683691 names 20 study sites across 13 states, led by Minnesota, New York, California.
Frequently Asked Questions
What is clinical trial NCT05683691 about?
NCT05683691 is a clinical study titled "Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer". The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
What is the current status of trial NCT05683691?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2023-05-16. Estimated completion is 2029-04.
What conditions does trial NCT05683691 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05683691?
The interventions under investigation include: Vanquish System (DEVICE).
Who is sponsoring clinical trial NCT05683691?
This trial is sponsored by Francis Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05683691 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05683691's enrollment target sits among peer trials
400 128th of 735 higher than 605 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI